drugset
drugset / Trial / NCT02922582

Study of Local Administration of DepoTXA for Reduced Postsurgical Bleeding in Subjects Undergoing TKA

NCT02922582 ↗

Phase 2 Terminated 16 enrolled Pacira Pharmaceuticals, Inc
RandomizedParallel-groupSingle-blindTreatment

Summary

This is a Phase 2, randomized, single-blind, active-controlled dose-ranging study in subjects scheduled to undergo total knee arthroplasty (TKA).

Timeline

Start
2016-10-28
Primary completion
2017-11-27
Completion
2017-11-27

Drugs

EvaluationDrugModalityDoseRoute
Subject DepoTXA Unknown 400 mg Other
Subject DepoTXA Unknown 800 mg Other
Subject DepoTXA Unknown 1200 mg Other
Comparator Tranexamic Acid Small molecule 1 g Intravenous

Indications

No indication recorded.